Metabolic tumor volume on 18F-fluorodeoxyglucose uptake as prognostic marker for osimertinib in patients with non-small cell lung cancer harboring sensitive EGFR mutation
Kosuke Hashimoto, Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Ou Yamaguchi, Ichiei Kuji, Hiroshi Kagamu · 2025
Read Metabolic tumor volume on 18F-fluorodeoxyglucose uptake as prognostic marker for osimertinib in patients with non-small cell lung cancer harboring sensitive EGFR mutation by Kosuke Hashimoto, Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Ou Yamaguchi, Ichiei Kuji, Hiroshi Kagamu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12775706.txt.
Description
Kosuke Hashimoto and co-authors test a scan measure as a warning sign for patients on a targeted lung cancer drug in a 2025 study. The drug, osimertinib, treats non-small cell lung cancer carrying a sensitive mutation in a growth gene. PET scans show how much sugar the tumor burns, and one measure, the total volume of active tumor, may reflect disease burden better than peak uptake alone.
Sixty-eight patients had scans before starting the drug. Spread to bone and liver tracked with high volume values. Response rates and side effects did not differ by scan uptake level. In adjusted analysis, the volume measure stood out as a predictor of how long patients lived without the cancer growing. The authors call it a significant marker for this treatment.
Catalog record
| CREATOR | Kosuke Hashimoto, Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Ou Yamaguchi, Ichiei Kuji, Hiroshi Kagamu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |